These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 21481708)

  • 41. Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model.
    Schleiss MR; Choi KY; Anderson J; Mash JG; Wettendorff M; Mossman S; Van Damme M
    Vaccine; 2014 May; 32(23):2756-62. PubMed ID: 23867012
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.
    Harro CD; Pang YY; Roden RB; Hildesheim A; Wang Z; Reynolds MJ; Mast TC; Robinson R; Murphy BR; Karron RA; Dillner J; Schiller JT; Lowy DR
    J Natl Cancer Inst; 2001 Feb; 93(4):284-92. PubMed ID: 11181775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin.
    Drulak MW; Malinoski FJ; Fuller SA; Stewart SS; Hoskin S; Duliege AM; Sekulovich R; Burke R; Winston S
    Viral Immunol; 2000; 13(1):49-56. PubMed ID: 10733168
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
    Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
    Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
    Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
    Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.
    Paya CV; Wilson JA; Espy MJ; Sia IG; DeBernardi MJ; Smith TF; Patel R; Jenkins G; Harmsen WS; Vanness DJ; Wiesner RH
    J Infect Dis; 2002 Apr; 185(7):854-60. PubMed ID: 11920308
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Das R; Blázquez-Gamero D; Bernstein DI; Gantt S; Bautista O; Beck K; Conlon A; Rosenbloom DIS; Wang D; Ritter M; Arnold B; Annunziato P; Russell KL;
    Lancet Infect Dis; 2023 Dec; 23(12):1383-1394. PubMed ID: 37660711
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial.
    Banham GD; Flint SM; Torpey N; Lyons PA; Shanahan DN; Gibson A; Watson CJE; O'Sullivan AM; Chadwick JA; Foster KE; Jones RB; Devey LR; Richards A; Erwig LP; Savage CO; Smith KGC; Henderson RB; Clatworthy MR
    Lancet; 2018 Jun; 391(10140):2619-2630. PubMed ID: 29910042
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and Immunogenicity of a Messenger RNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial.
    Fierro C; Brune D; Shaw M; Schwartz H; Knightly C; Lin J; Carfi A; Natenshon A; Kalidindi S; Reuter C; Miller J; Panther L
    J Infect Dis; 2024 Sep; 230(3):e668-e678. PubMed ID: 38478705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine.
    Frey SE; Harrison C; Pass RF; Yang E; Boken D; Sekulovich RE; Percell S; Izu AE; Hirabayashi S; Burke RL; Duliège AM
    J Infect Dis; 1999 Nov; 180(5):1700-3. PubMed ID: 10515836
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytomegalovirus vaccine: persistence of humoral immunity following immunization of renal transplant candidates.
    Sachs GW; Simmons RL; Balfour HH
    Vaccine; 1984 Sep; 2(3):215-8. PubMed ID: 6099649
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
    Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
    Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
    Dagnew AF; Ilhan O; Lee WS; Woszczyk D; Kwak JY; Bowcock S; Sohn SK; Rodriguez Macías G; Chiou TJ; Quiel D; Aoun M; Navarro Matilla MB; de la Serna J; Milliken S; Murphy J; McNeil SA; Salaun B; Di Paolo E; Campora L; López-Fauqued M; El Idrissi M; Schuind A; Heineman TC; Van den Steen P; Oostvogels L;
    Lancet Infect Dis; 2019 Sep; 19(9):988-1000. PubMed ID: 31399377
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.
    Marty FM; Ljungman P; Papanicolaou GA; Winston DJ; Chemaly RF; Strasfeld L; Young JA; Rodriguez T; Maertens J; Schmitt M; Einsele H; Ferrant A; Lipton JH; Villano SA; Chen H; Boeckh M;
    Lancet Infect Dis; 2011 Apr; 11(4):284-92. PubMed ID: 21414843
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Comparison of the CMV antigenemia test and CMV-DNA PCR results in solid organ transplant recipients].
    Özkarata E; Özbek ÖA; Avkan Oğuz V; Sayıner AA
    Mikrobiyol Bul; 2016 Jan; 50(1):44-52. PubMed ID: 27058328
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.
    Essink B; Chu L; Seger W; Barranco E; Le Cam N; Bennett H; Faughnan V; Pajon R; Paila YD; Bollman B; Wang S; Dooley J; Kalidindi S; Leav B
    Lancet Infect Dis; 2023 May; 23(5):621-633. PubMed ID: 36682364
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects.
    Adler SP; Lewis N; Conlon A; Christiansen MP; Al-Ibrahim M; Rupp R; Fu TM; Bautista O; Tang H; Wang D; Fisher A; Culp T; Das R; Beck K; Tamms G; Musey L;
    J Infect Dis; 2019 Jul; 220(3):411-419. PubMed ID: 31535143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.